ストックスクリーナーアプリを入手
13.99
4.31%
-0.63
前日終値:
$14.62
開ける：
$14.78
24時間の取引高:
582.26K
Relative Volume:
0.81
時価総額：
$885.87M
収益：
$202.09M
当期純損益:
$-61.69M
株価収益率:
-12.95
EPS:
-1.08
ネットキャッシュフロー:
$-35.64M
1週間 パフォーマンス:
-5.09%
1か月 パフォーマンス:
+3.78%
6か月 パフォーマンス:
-10.66%
1年 パフォーマンス:
+7.04%
1日の値動き範囲:
$13.79
$14.78
1週間の範囲:
$13.79
$15.06
52週間の値動き範囲:
$9.25
$17.82
Evolus Inc Stock (EOLS) Company Profile
EOLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
13.99 | 885.87M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 開始されました | Needham | Buy |
| 2022-05-12 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2021-05-06 | アップグレード | Mizuho | Neutral → Buy |
| 2021-04-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-24 | ダウングレード | Truist | Buy → Hold |
| 2020-07-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-02-06 | 再開されました | Mizuho | Buy |
| 2019-11-26 | 開始されました | SVB Leerink | Outperform |
| 2019-09-05 | 再開されました | Mizuho | Buy |
| 2019-06-28 | 開始されました | Wells Fargo | Market Perform |
| 2019-06-11 | 開始されました | Barclays | Underweight |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-29 | 開始されました | Stifel | Buy |
すべてを表示
Evolus Inc (EOLS) 最新ニュース
Rice Hall James & Associates LLC Acquires 43,381 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit - BioSpace
Inside Evolus's Growth Strategy: CEO Takes Center Stage at Elite Beauty Summit - StockTitan
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 - BioSpace
Evolus Sets Date for Key 2024 Financial Results: What the Beauty Industry is Watching - StockTitan
Evolus (NASDAQ:EOLS) Receives Buy Rating from HC Wainwright - MarketBeat
Legato Capital Management LLC Sells 43,769 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus (NASDAQ:EOLS) Trading 15.3% HigherTime to Buy? - MarketBeat
Evolus's SWOT analysis: FDA nod for filler boosts stock outlook By Investing.com - Investing.com Australia
Merck KGaA bids for SpringWorks (SWTX), Evolus (EOLS) receives FDA nod & Prothena (PRTA) struggles - substack.com
Evolus's SWOT analysis: FDA nod for filler boosts stock outlook - MSN
Evolus’s SWOT analysis: FDA nod for filler boosts stock outlook By Investing.com - Investing.com Nigeria
(EOLS) Technical Data - Stock Traders Daily
Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last? - MSN
FDA approves two hyaluronic acid fillers for nasolabial folds - Healio
FDA Approves Two New Hyaluronic Acid Dermal Fillers - Medical Dialogues
Breaking Down Evolus: 4 Analysts Share Their Views - Benzinga
A great week that adds to Evolus, Inc.'s (NASDAQ:EOLS) one-year returns, institutional investors who own 70% must be happy - Simply Wall St
Sector Update: Health Care -February 13, 2025 at 03:38 pm EST - Marketscreener.com
Evolus Gets US FDA Approval for Injectable Hyaluronic Acid Gels -February 13, 2025 at 02:11 pm EST - Marketscreener.com
US FDA approves Evolus' anti-wrinkle gels - TradingView
US FDA approves Evolus' anti-wrinkle gels -February 13, 2025 at 02:02 pm EST - Marketscreener.com
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - Business Wire
Game-Changing FDA Approval: Evolus Unveils Next-Gen Dermal Fillers That Outperform Restylane - StockTitan
With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing - Yahoo Finance
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 - BioSpace
Evolus (NASDAQ:EOLS) Trading Down 6.5%Here's Why - MarketBeat
Unlocking Beauty: Evolus Sparks Excitement with New Stock Awards for Employees! - Mi Valle
Acelyrin (NASDAQ:SLRN) versus Evolus (NASDAQ:EOLS) Financial Contrast - Defense World
Unlocking Beauty: Evolus Rewards New Talent with Stock Options and RSUs - Trabajo News
Evolus Unleashes Major Talent Expansion: 34 New Hires Secure Equity Stakes in Growth Push - StockTitan
BlackRock, Inc. Expands Stake in Evolus Inc with Strategic Acqui - GuruFocus.com
How the (EOLS) price action is used to our Advantage - Stock Traders Daily
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Barclays Issues Positive Forecast for Evolus (NASDAQ:EOLS) Stock Price - Defense World
Global Jeuveau Market Insights 2025: Key Trends, Market Size, and Growth Forecast - EIN News
Barclays Raises Evolus (NASDAQ:EOLS) Price Target to $22.00 - MarketBeat
Stifel maintains Buy on Evolus, price target steady at $25 - MSN
HC Wainwright Issues Optimistic Outlook for Evolus Earnings - Defense World
Midday Stock Roundup: Virgin Galactic down 2.3% and 87% YoY - Orange County Business Journal
FY2029 Earnings Estimate for Evolus Issued By HC Wainwright - MarketBeat
HC Wainwright Weighs in on Evolus' Q4 Earnings (NASDAQ:EOLS) - MarketBeat
Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? - MSN
Evolus, Inc. (NASDAQ:EOLS) Soars 30% But It's A Story Of Risk Vs Reward - Simply Wall St
HC Wainwright Reaffirms "Buy" Rating for Evolus (NASDAQ:EOLS) - MarketBeat
4 Analysts Have This To Say About Evolus - Benzinga
Evolus projects robust 2025 growth with upcoming product launches By Investing.com - Investing.com Australia
Evolus Inc (EOLS) 財務データ
収益
当期純利益
現金流量
EPS
3.23%
3.94%
大文字化:
|
ボリューム (24 時間):